Which of the following is the first combination pill approved to treat chronic HCV genotype 1 infection?
Answer: (d). Ledipasvir and Sofosbuvir (Harvoni) . Ledipasvir and Sofosbuvir (Harvoni) is the first combination pill approved to treat chronic HCV genotype 1 infection.
Harvoni is a fixed-dose combination of ledipasvir, a hepatitis C virus (HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor, and is indicated for the treatment of chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years of age and older:
1. Genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis.
2. Genotype 1 infection with decompensated cirrhosis, in combination with ribavirin.
3. Genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, in combination with ribavirin.
It is available as tablets (90mg Ledipasvir/400 mg Sofosbuvir, 45mg Ledipasvir/200 mg Sofosbuvir) and oral pellets (45 mg of Ledipasvir and 200 mg of Sofosbuvir, 33.75 mg of Ledipasvir and 150 mg of Sofosbuvir).
The recommended dose in an adult patient is one tablet (90 mg of Ledipasvir and 400 mg of Sofosbuvir) taken orally once daily with or without food.
The most common side effects reported in clinical trial participants were fatigue and headache.
Try Naplex QBank. www.pharmacyexam.com